Anthropic-, Nvidia-Backed Basecamp Research Raise $140M Series C Financing Toward Advancing AI-Designed Drugs
According to Basecamp, EDEN offers the ability to design long and complex DNA sequences with large serine recombinases capable of delivering those sequences precisely. The post Anthropic-, Nvidia-Backed Basecamp Research Raise $140M Series C Financing Toward Advancing AI-Designed Drugs appeared first on GEN - Genetic Engineering and Biotechnology News .
Basecamp Research announced it has secured $140 million in Series C financing to develop advanced in vivo cell therapies using its proprietary EDEN foundation model. EDEN, short for "environmentally-derived evolutionary network," is a biological foundation model trained on the world's largest and most diverse evolutionary dataset.
This model enables Basecamp to design long and complex DNA sequences with large serine recombinases, allowing for precise delivery of therapeutic sequences within the human genome. The funding, led by Anthropic through its Anthology Fund, aims to bring AI-based therapeutic design closer to patients who desperately need improved treatment options.
Anthropic's co-founder and president, Daniela Amodei, emphasized their interest in ventures leveraging AI to enhance human capabilities, particularly in healthcare. Basecamp's EDEN-designed therapies show promise in treating complex diseases like cancer and autoimmune disorders, offering a more sophisticated, customizable, and simpler administration compared to current cell therapies.
With strong preclinical results across multiple modalities and disease areas, Basecamp's technology aims to revolutionize medicine by reprogramming the body to repair itself.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
